The rise of pills marketed for women’s confidence reveals the intersection of gender, medicine, capitalism, and the unfinished politics of liberation.

Confidence has long been a contested resource. For men, it is assumed; for women, it is prescribed. Across the twentieth century, women fought for the right to vote, to work, to control their bodies. By the twenty-first, another frontier emerged: the right to feel adequate in a world designed to diminish them. Now, in 2025, a pill promises to deliver what centuries of social conditioning have withheld—confidence. Marketed as a biochemical shortcut to self-assurance, it is the latest emblem of how gender, medicine, and capitalism intersect. But what does it mean when confidence itself is commodified? And why does the demand for such a pill tell us more about society’s failures than women’s shortcomings?
This is not simply a story about pharmacology. It is about power.
To understand the confidence pill, one must trace the lineage of how medicine has historically framed women. From “hysteria” in the nineteenth century to Prozac in the 1990s, the female body has been treated as a site of correction. Pills have been prescribed not only to treat illness but to manage behaviour, to conform women to systems never built for them. The contraceptive pill in the 1960s was revolutionary—granting women unprecedented control over reproduction. Yet even that liberation was framed within male-dominated institutions of science and commerce. The confidence pill is the latest iteration. It suggests that rather than dismantling systems that erode women’s self-assurance, society will provide capsules to compensate. The body must adapt, not the culture.
Pharmacologically, the pill in question combines mild stimulants with mood regulators designed to enhance dopamine and serotonin levels. Scientifically, it is not radically different from existing antidepressants or anti-anxiety medication. The difference lies in branding. It is sold not as treatment but as enhancement. Not as therapy but as empowerment. Glossy advertisements promise not relief from disorder but the arrival of confidence itself: “Be Bold. Be Fearless. Be You—Now in One Dose.” This reframing is crucial. The pharmaceutical industry has realised that aspiration sells better than pathology. Confidence is marketable. And in a culture saturated with self-help rhetoric, the promise of instant self-belief is irresistible.
The confidence pill thrives because capitalism excels at turning insecurity into profit. Beauty standards, workplace hierarchies, and social expectations generate the very anxieties that pills then claim to solve. A woman underpaid compared to male colleagues may feel inadequate. Rather than reform wage structures, society offers her a pill. A teenager pressured by Instagram perfection may feel inferior. Rather than regulate platforms, society offers her a capsule. The confidence pill is thus less about empowerment than about adaptation. It allows women to cope with unjust systems rather than transform them. In this sense, it is not liberation but pacification dressed as progress.
Confidence itself is complex. It is not merely biochemical. It is relational, social, cultural. It arises from recognition, opportunity, and respect. To suggest it can be swallowed is to reduce it to chemistry alone. Yet the appeal is undeniable. Confidence is currency in workplaces, in politics, in relationships. Women denied it structurally are understandably drawn to any means of levelling the field. The pill offers not only dopamine but hope.
But hope mediated through pharmacology is fragile. What happens when the pill wears off? What happens when reliance replaces resilience Feminist scholars are divided. Some argue that the confidence pill, like the contraceptive pill before it, expands agency. Women should have the choice to alter their neurochemistry if it empowers them. Others counter that it medicalises social injustice, making women responsible for overcoming barriers that society should dismantle. The ethical debate is profound. Does empowerment through chemistry reinforce the very systems it seeks to escape? Or is every tool valid in the fight for agency? The answer may be both. Liberation is rarely pure. Tools can be co-opted even as they empower.
Nowhere is the confidence pill more evident than in the workplace. Surveys show women increasingly turn to enhancement drugs before major presentations, interviews, or negotiations. Employers, often quietly complicit, benefit from the performance boost without addressing structural inequities. The risk is clear: confidence becomes another metric of productivity, another resource to be optimised. The woman who refuses the pill may be seen as lacking drive. Enhancement becomes expectation. Choice becomes coercion. In this way, the pill risks reproducing the very inequities it claims to remedy.
The phenomenon is not confined to America. In Asia, pills marketed for confidence blur with supplements promising beauty and slimness. In Europe, debates rage over whether such pills should be regulated as medicine or lifestyle products. In Africa and Latin America, access disparities highlight the global inequality of pharmacological empowerment. The global market for “confidence enhancers” is projected to reach billions. But access is stratified. Privileged women may buy empowerment in capsules. Marginalised women remain excluded, reinforcing the hierarchies of class and race. The confidence pill is part of a broader trend of human enhancement. Nootropics for focus, stimulants for productivity, psychedelics for creativity—the body is increasingly seen as a site of optimisation.
The danger is that humanity begins to outsource identity to chemistry. If confidence, creativity, and resilience are all medicated, what remains of the unaltered self? What happens to societies that demand perpetual enhancement? The risk is not only addiction to substances but addiction to the very idea that identity must be engineered to fit capitalism’s demands.
The pill women are taking for confidence matters not because it is revolutionary medicine, but because it symbolises a deeper crisis. It reveals a society more willing to prescribe adaptation than pursue justice. It shows how capitalism commodifies even the most intimate of human traits. It underscores how gendered inequities persist, repackaged as empowerment. This still matters because confidence should not be a pill. It should be a birthright of dignity, opportunity, and equality. Until society confronts the systems that erode women’s self-assurance, no capsule can deliver true empowerment. The question is not whether women should take the pill. The question is why society keeps forcing them to.
Anonymous is a private guest contributor of WTM MEDIA. Through Why These Matter, they examines the intersections of medicine, healthcare, and design—bringing clarity to issues that shape people, influence culture, and determine the future of global society.

Most people believe David Beckham changed football in America because he was a great footballer. They are only partially correct. His greatest contribution had little to do with goals, trophies, or free kicks. Beckham helped redesign how America perceived the world’s most popular sport. His arrival accelerated investment, attracted international attention, reshaped Major League Soccer’s commercial strategy, encouraged youth participation, and demonstrated that culture can cross borders when trust arrives before the product. This is not simply the story of one athlete. It is a lesson in leadership, branding, economics, psychology, and institutional strategy. Every business seeking to enter a new market can learn from what Beckham accomplished without ever intending to become a case study in global systems thinking.

Twenty years after The Devil Wears Prada became one of the defining cultural films of the early twenty-first century, its sequel arrives with a noticeably different ambition. Rather than attempting to recreate the sharp glamour and quotable brilliance of the original, The Devil Wears Prada 2 examines what happens when an institution built for one era must survive another. Critics and audiences broadly agree that while the sequel lacks a cultural moment comparable to Miranda Priestly’s famous cerulean monologue, it succeeds by shifting the conversation from personal ambition to organisational adaptation. The film’s strongest contribution is not fashion, nostalgia or celebrity. It is its quiet recognition that industries age in much the same way people do. Print journalism confronts digital platforms. Hierarchical leadership collides with collaborative workplaces. Authority becomes accountable to governance. Influence competes with algorithms. The result is a story that reflects a broader transformation occurring across media, business and society. What appears to be a sequel about fashion is, in reality, an examination of institutional resilience in an era of accelerating disruption.

For more than two centuries, work has been organised around a simple assumption: people travel to places where economic activity occurs. Factories required physical presence. Offices centralised coordination. Cities emerged as concentrations of labour, capital, and opportunity. COVID-19 shattered this assumption almost overnight. Remote work demonstrated that many knowledge-based professions were never dependent upon offices themselves but upon the coordination functions offices provided. Simultaneously, artificial intelligence has begun transforming the nature of labour itself, automating cognitive tasks once considered immune to technological disruption. Together, these forces are producing a fundamental redesign of work. The future is not a world without jobs. It is a world where work becomes increasingly distributed, augmented, fluid, and continuously adaptive. The office was never the point. Coordination was. The organisations, workers, and societies that understand this distinction may gain extraordinary advantages in the decades ahead.